Neonatal Lung Ultrasound in RDS: LUS Score and Surfactant Threshold — МЕДТРЕЙН Asia
Ultrasound Diagnostics in Pediatrics

Neonatal Lung Ultrasound in RDS: LUS Score and Surfactant Threshold

Briefly. The neonatal Lung Ultrasound Score (LUS) is a bedside, radiation-free semi-quantitative tool that predicts the need for surfactant administration in preterm infants with respiratory distress syndrome (RDS) on CPAP. The classical Brat–De Luca scale (2015) assesses 6 zones (3 per lung), each scored 0–3 points, with a total range of 0–18. There is no single universal threshold, but in infants <34 weeks, a threshold of ≥4 demonstrated 100% sensitivity with 61% specificity. The European Consensus on RDS (2022) permits surfactant administration "if lung ultrasound indicates the need" (level B2). The decision is always made in conjunction with clinical findings and oxygen requirements.

What is the Neonatal LUS Score

Lung ultrasound (LUS) is a bedside, radiation-free method applicable in neonatal intensive care for assessing lung aeration. The semi-quantitative score proposed by Brat et al. (2015) and further developed by the De Luca/Raimondi group has become the most widely used neonatal scale. Each lung is divided into three zones — upper anterior, lower anterior, and lateral; a total of six regions are assessed (right and left upper anterior, lower anterior, and lateral).

Grading of Each Zone (0–3 Points)

ScoreUltrasound AppearanceAeration
0A-lines only (horizontal repeats of the pleural line)Normal
1≥3 separate (discrete) B-linesModerately reduced
2Confluent B-lines ("white lung"), ± subpleural consolidationsSignificantly reduced
3Extensive consolidation with air bronchogramsSeverely reduced

Scores from six zones are summed to yield a total LUS score of 0–18: higher scores indicate worse aeration. Extended versions of the scale exist (10 or 12 zones, including posterior fields), but the 6-zone anterior-lateral scheme is the primary validated approach for surfactant decisions.

Threshold for Surfactant Administration

There is no single universal threshold value: the specific threshold depends on the scale version, gestational age, and reference standard (systematic review by Capasso/Raimondi, 2023). Key findings:

StudyPopulationThreshold / IndicatorAccuracy
Brat, 2015 (JAMA Pediatr)<34 weeks on CPAPLUS ≥4Sensitivity 100%, specificity 61%; AUC 0.93
De Martino, 2018 (Pediatrics)≤30 weeks on CPAPfirst doseAUC 0.94; accuracy 89% (repeat dose AUC 0.80)
Aldecoa-Bilbao, 2020 (Pediatr Pulmonol)<32 weeksSpO₂/FiO₂ model + LUSAUC 0.95–0.97
Capasso/Raimondi, 2023 (meta-analysis, 697 infants)pretermvarious thresholdsPooled sensitivity 89%, specificity 86%; AUC 0.88

In summary (meta-analysis of 7 studies, 697 infants): LUS score predicts the need for first-dose surfactant with sensitivity 89% and specificity 86% (AUC 0.88), despite variation in thresholds across studies.

What Guidelines Recommend

The European Consensus Guidelines on the Management of RDS (Sweet et al., 2022) note that "lung ultrasound, when properly performed, can serve as a method for earlier diagnosis of RDS, apparently without increasing the overall number of treated infants." In the proposed protocol, surfactant is administered to a deteriorating infant with RDS "when FiO₂ > 0.30 on CPAP with pressure ≥6 cm H₂O or if lung ultrasound indicates the need for surfactant" (evidence level B2).

Clinical Benefit of LUS-Guided Strategy

In a randomized controlled trial (Zhang et al., 2025; preterm infants <32 weeks), a strategy combining RDS diagnosis by ultrasound and surfactant administration by LUS criteria reduced the frequency and duration of invasive mechanical ventilation, allowed earlier administration of the first dose, and reduced total surfactant volume. It also decreased radiation exposure during the first week of life. Predictive models combining LUS with the SpO₂/FiO₂ ratio (Aldecoa-Bilbao, 2020) achieve AUC 0.95–0.97 and enable anticipatory surfactant administration—within 2 hours of life.

Limitations

  • Operator-dependence and learning curve; standardization of scanning zones and device settings is necessary.
  • Threshold values do not transfer directly between scale versions and devices (threshold variability—Capasso/Raimondi, 2023).
  • LUS complements but does not replace clinical assessment and FiO₂ monitoring; the final decision on surfactant remains multifactorial.

Frequently asked questions

What LUS score threshold indicates the need for surfactant?

There is no single universal threshold. In the original Brat scale (infants <34 weeks on CPAP), a threshold of ≥4 demonstrated 100% sensitivity with 61% specificity. The specific threshold depends on the scale version, gestational age, and clinical context.

How is the neonatal LUS score structured?

Each lung is divided into 3 zones (upper anterior, lower anterior, lateral)—totaling 6 regions; each is scored 0–3 points (0 = A-lines, 3 = extensive consolidation). The sum of all zones yields a total score of 0–18.

How accurate is LUS for predicting surfactant need?

According to a meta-analysis of 7 studies (697 infants)—sensitivity 89%, specificity 86% (AUC 0.88); in extremely preterm infants AUC reaches 0.94 (De Martino, 2018).

What does the European Consensus on RDS (2022) recommend?

Administer surfactant to a deteriorating infant with RDS when FiO₂ > 0.30 on CPAP with pressure ≥6 cm H₂O or if lung ultrasound indicates the need for surfactant (evidence level B2).

Does LUS replace clinical assessment and FiO₂ monitoring?

No. LUS complements clinical evaluation and oxygen monitoring; the final decision on surfactant administration remains multifactorial.

The material is intended for specialists and does not replace clinical judgment. Threshold values are periodically reviewed — refer to the current edition of the applicable consensus.
Sources: Brat R, et al. Lung Ultrasonography Score to Evaluate Oxygenation and Surfactant Need in Neonates Treated With CPAP. JAMA Pediatr. 2015;169(8):e151797. https://doi.org/10.1001/jamapediatrics.2015.1797 — De Martino L, et al. Lung Ultrasound Score Predicts Surfactant Need in Extremely Preterm Neonates. Pediatrics. 2018;142(3):e20180463. https://doi.org/10.1542/peds.2018-0463 — Aldecoa-Bilbao V, et al. Lung ultrasound for early surfactant treatment: development and validation of a predictive model. Pediatr Pulmonol. 2021;56(2):433-441. https://doi.org/10.1002/ppul.25216 — Capasso L, et al. Can lung ultrasound score accurately predict surfactant replacement? A systematic review and meta-analysis. Pediatr Pulmonol. 2023;58(5):1427-1437. https://doi.org/10.1002/ppul.26337 — Zhang J, et al. RCT of Pulmonary Surfactant Administration Guided by Lung Ultrasound in Preterm Infants <32 Weeks. Children (Basel). 2025;12(12):1618. https://doi.org/10.3390/children12121618 — Sweet DG, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology. 2023;120(1):3-23. https://doi.org/10.1159/000528914
View specialty courses: Pediatric Ultrasound →
Спросить Alex Отвечу на любой вопрос · 24/7 · на любом языке